What do we know about memory B cells in primary Sjogren's syndrome?

被引:25
作者
Hansen, Arne [1 ,2 ]
Daridon, Capucine [3 ]
Doerner, Thomas [3 ]
机构
[1] Akad Lehrkrankenhaus Charite, Pk Klink Weissensee, Dept Med, D-13086 Berlin, Germany
[2] Charite, Outpatients Dept Med, Berlin, Germany
[3] Charite, Dept Rheumatol & Clin Immunol, Berlin, Germany
关键词
Primary Sjogrens syndrome; Autoimmunity; Memory B cells; Lymphoma; Rituximab; DEPRESSED PERCENTAGE; AUTOIMMUNE-DISEASES; SALIVARY-GLANDS; BLOOD; EXPRESSION; RITUXIMAB; CD27; HETEROGENEITY; CORRELATE; LYMPHOMA;
D O I
10.1016/j.autrev.2010.05.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Abnormalities of memory B cells seem to be closely involved in the pathogenesis of primary Sjogrens Syndrome (pSS) and its malignant complication, B cell lymphoma. Recent studies on B cells in pSS add to our understanding of the distinct memory B cell subsets in pSS. Reduction of peripheral memory CD27(+) B cells, most strikingly of the CD27(+) IgM(+) subset, may indicate a lack of appropriate censoring mechanisms and Incomplete differentiation processes within the ectopic lymphoid tissues in pSS. This ectopically formed lymphoid tissue might protect autoreactive memory B cells from deletion by physiological check-points and, thereby, may contribute to the perpetuation of the disease as well as to an enhanced lymphoma risk. Thus, B cells may be potential targets of direct or indirect treatment in pSS (C) 2010 Elsevier B V All rights reserved
引用
收藏
页码:600 / 603
页数:4
相关论文
共 50 条
  • [31] Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome
    Abdulahad, Wayel H.
    Kroese, Frans G. M.
    Vissink, Arjan
    Bootsma, Hendrika
    JOURNAL OF AUTOIMMUNITY, 2012, 39 (1-2) : 103 - 111
  • [32] Efficacy and safety of biological DMARDs modulating B cells in primary Sjogren's syndrome: Systematic review and meta-analysis
    Letaief, Hind
    Lukas, Cedric
    Barnetche, Thomas
    Gaujoux-Viala, Cecile
    Combe, Bernard
    Morel, Jacques
    JOINT BONE SPINE, 2018, 85 (01) : 13 - 20
  • [33] Progressive Supranuclear Palsy: What Do We Know About it?
    Long, Ling
    Cai, Xiao-Dong
    Wei, Xiao-Bo
    Liao, Jin-Chi
    Xu, Yun-Qi
    Gao, Hui-Min
    Chen, Xiao-Hong
    Wang, Qing
    CURRENT MEDICINAL CHEMISTRY, 2015, 22 (10) : 1182 - 1193
  • [34] Identification of the key genes and pathways involved in B cells in primary Sjogren' s syndrome
    Lei, Shizhen
    Zhang, Yi
    BIOENGINEERED, 2021, 12 (01) : 2055 - 2073
  • [35] Immune privilege of skin stem cells: What do we know and what can we learn?
    Agudo, Judith
    EXPERIMENTAL DERMATOLOGY, 2021, 30 (04) : 522 - 528
  • [36] Classification criteria and treatment modalities in primary Sjogren's syndrome
    Fazaa, Alia
    Bourcier, Tristan
    Chatelus, Emmanuel
    Sordet, Christelle
    Theulin, Arnaud
    Sibilia, Jean
    Gottenberg, Jacques-Eric
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (04) : 543 - 551
  • [37] Primary Sjogren's syndrome: Pathophysiological, clinical and therapeutic advances
    Gottenberg, J. -E.
    JOINT BONE SPINE, 2009, 76 (06) : 591 - 594
  • [38] Immunoregulatory effects of dental mesenchymal stem cells on T and B lymphocyte responses in primary Sjogren's syndrome
    Genc, Deniz
    Gunaydin, Burcu
    Sezgin, Serhat
    Aladag, Akin
    Tarhan, Emine Figen
    IMMUNOTHERAPY, 2022, 14 (04) : 225 - 247
  • [39] B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome
    Nezos, Adrianos
    Papageorgiou, Aristea
    Fragoulis, George
    Ioakeimidis, Dimitrios
    Koutsilieris, Michael
    Tzioufas, Athanasios G.
    Moutsopoulos, Haralampos M.
    Voulgarelis, Michael
    Mavragani, Clio P.
    JOURNAL OF AUTOIMMUNITY, 2014, 51 : 89 - 98
  • [40] Feline Oncogenomics: What Do We Know about the Genetics of Cancer in Domestic Cats?
    Ludwig, Latasha
    Dobromylskyj, Melanie
    Wood, Geoffrey A.
    van der Weyden, Louise
    VETERINARY SCIENCES, 2022, 9 (10)